{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:31:20Z","timestamp":1795059080035,"version":"4.10.2"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128491","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:51:56Z","timestamp":1774025516000},"page":"128491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)"],"prefix":"10.1016","volume":"79","author":[{"given":"Gerard Timmy","family":"Vondeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Croda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kassianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Kollaritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liem Binh Luong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Sousa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Schmidt-Chanasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne","family":"de Roo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Plennevaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128491_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010069","article-title":"The global epidemiology of chikungunya from 1999 to 2020: a systematic literature review to inform the development and introduction of vaccines","volume":"16","author":"Bettis","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128491_bb0010","series-title":"Seasonal surveillance of chikungunya virus disease in the EU\/EEA, weekly report","author":"European Centre for Disease Prevention and Control","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128491_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012254","article-title":"Clinical outcomes of chikungunya: a systematic literature review and meta-analysis","volume":"18","author":"Rama","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128491_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2024.02.011","article-title":"Pathophysiology of chikungunya virus infection associated with fatal outcomes","volume":"32","author":"de Souza","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128491_bb0025","article-title":"The neurological complications of chikungunya virus: a systematic review","volume":"28","author":"Mehta","year":"2018","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2026.128491_bb0030","article-title":"The approved live-attenuated chikungunya virus vaccine (IXCHIQ(\u00ae)) elicits cross-neutralizing antibody breadth extending to multiple arthritogenic alphaviruses similar to the antibody breadth following natural infection","volume":"12","author":"Weber","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128491_bb0035","series-title":"IXCHIQ (live chikungunya vaccine) \u2013 Chikungunya","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128491_bb0040","series-title":"Weekly communicable disease threats report, Week 20, 10\u201316 May 2025","author":"European Centre for Disease Prevention and Control","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128491_bb0045","series-title":"Assessment report: Procedure under Article 20 of Regulation (EC) No 726\/2004 resulting from pharmacovigilance data","author":"European Medicines Agency","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128491_bb0050","series-title":"Referral procedures: human medicines","author":"European Medicines Agency","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128491_bb0055","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.32.2500543","article-title":"Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025","volume":"30","author":"Hills","year":"2025","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128491_bb0060","series-title":"FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128491_bb0065","series-title":"CATMAT guidance on the use of the live-attenuated chikungunya vaccine (IXCHIQ) in persons 65 years or older","author":"Government of Canada","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128491_bb0070","series-title":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) \u2013 Module VI: Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). EMA\/873138\/2011 Rev 2","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128491_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae133","article-title":"Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine\u2020","volume":"31","author":"Maurer","year":"2024","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2026.128491_bb0080","series-title":"ANNEX I \u2013 Summary of Product Characteristics. European Commission, Directorate-General for Health and Food Safety","author":"European Comission","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128491_bb0085","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128491_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad156","article-title":"A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults\u2020","volume":"31","author":"McMahon","year":"2024","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2026.128491_bb0095","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(24)00357-8","article-title":"Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study","volume":"24","author":"McMahon","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128491_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae084","article-title":"Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine","volume":"31","author":"Buerger","year":"2024","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2026.128491_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf550","article-title":"Fatal adverse event after VLA1553 chikungunya vaccination in an elderly patient: a case report from Reunion Island","volume":"12","author":"Mosnier","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128491_bb0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(25)00552-3","volume":"25","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128491_bb0115","series-title":"Disease Outbreak News; Chikungunya in La R\u00e9union and Mayotte","author":"World Health Organization","year":"2025"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128491_bb0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/v18020180","article-title":"Increased mortality rate during 2025 chikungunya epidemic in R\u00e9union Island","volume":"18","author":"Ribas Freitas","year":"2026","journal-title":"Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:54:38Z","timestamp":1781308478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"alternative-id":["S0264410X26002999"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128491","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128491"}}